Keith Westby - Feb 17, 2023 Form 4 Insider Report for IVERIC bio, Inc. (ISEE)

Signature
/s/ Todd D.C. Anderman, as Attorney-in-Fact for Keith Westby
Stock symbol
ISEE
Transactions as of
Feb 17, 2023
Transactions value $
-$375,750
Form type
4
Date filed
2/22/2023, 04:52 PM
Previous filing
Feb 3, 2023
Next filing
Mar 6, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ISEE Common Stock Options Exercise $11.1K +3.79K +8.17% $2.94* 50.1K Feb 17, 2023 Direct F1
transaction ISEE Common Stock Sale -$94.8K -3.79K -7.55% $25.05 46.4K Feb 17, 2023 Direct F1, F2
transaction ISEE Common Stock Options Exercise $50.7K +11.2K +24.19% $4.52* 57.6K Feb 17, 2023 Direct F1
transaction ISEE Common Stock Sale -$281K -11.2K -19.48% $25.05 46.4K Feb 17, 2023 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ISEE Stock Option (right to buy) Options Exercise -$11.1K -3.79K -2.52% $2.94* 146K Feb 17, 2023 Common Stock 3.79K $2.94 Direct F1, F3
transaction ISEE Stock Option (right to buy) Options Exercise -$50.7K -11.2K -18.69% $4.52* 48.8K Feb 17, 2023 Common Stock 11.2K $4.52 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sale reported on this form was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 16, 2022.
F2 The sale price of the Reporting Person's shares represents the weighted average price of all shares sold by a broker in multiple transactions effected at prices ranging from $25.00 to $25.14 per share on February 17, 2023. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Registrant or a security holder of the Registrant, information regarding the number of shares sold at each price within the range.
F3 This stock option award was granted on December 19, 2017 and vested with respect to 25% of the shares subject to the option on the first anniversary of the grant date and with respect to the remaining shares in approximately equal monthly installments through the fourth anniversary of the grant date.
F4 This stock option award was granted on January 30, 2017 and vested with respect to 25% of the shares subject to the option on the first anniversary of the grant date and with respect to the remaining shares in approximately equal monthly installments through the fourth anniversary of the grant date.